Health Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors James Pereira Jul 21, 2023 – Recognized biopharma commercialization and market access leader to support Coherus’ strategic vision and multiple… Read More...
Health Coherus BioSciences to Present at Upcoming Investor Conferences in May James Pereira May 5, 2023 <!-- Name:DistributionId Value:8832592 --> <!--… Read More...
Health Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022 James Pereira Sep 19, 2022 - CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all… Read More...
Health FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar… James Pereira Aug 3, 2022 - CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023… Read More...
Health Coherus BioSciences Reports First Quarter 2022 Results James Pereira May 6, 2022 – CIMERLI™ BLA review progressing toward August 2022 action date –– Toripalimab BLA resubmission expected by mid-summer… Read More...
Health Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation… James Pereira Apr 17, 2022 REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”,… Read More...
Health Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at… James Pereira Mar 23, 2022 REDWOOD CITY, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today… Read More...
Health Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3… James Pereira Mar 15, 2022 – Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary… Read More...
Health Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of… James Pereira Mar 5, 2022 - Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with… Read More...
Health Coherus BioSciences Secures Credit Financing with Pharmakon Advisors James Pereira Jan 8, 2022 REDWOOD CITY, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq:… Read More...